Jefferies downgrades Alnylam stock rating on valuation concerns
Jefferies has downgraded its stock rating on Alnylam Pharmaceuticals due to valuation concerns. The downgrade signals that analysts believe the stock may be overpriced relative to its current fundamentals.
Alnylam Pharmaceuticals Jefferies stock downgrade biotech pharma